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The USH2A gene is mutated in patients with Usher syndrome type IIa, which is the most common subtype of
Usher syndrome and is characterized by hearing loss and retinitis pigmentosa. Since mutation analysis by DNA
sequencing of exons 1–21 revealed only ∼63% of the expected USH2A mutations, we searched for so-far-unchar-
acterized exons of the gene. We identiﬁed 51 novel exons at the 3′ end of the gene, and we obtained indications
for alternative splicing. The putative protein encoded by the longest open reading frame harbors, in addition to
the known functional domains, two laminin G and 28 ﬁbronectin type III repeats, as well as a transmembrane
region followed by an intracellular domain with a PDZ-binding domain at its C-terminal end. Semiquantitative
expression proﬁle analysis suggested a low level of expression for both the long and the short isoform(s) and partial
overlap in spatial and temporal expression patterns.Mutation analysis in 12 unrelated patientswithUsher syndrome,
each with one mutation in exons 1–21, revealed three different truncating mutations in four patients and two
missense mutations in one patient. The presence of pathogenic mutations in the novel exons indicates that at least
one of the putative long isoforms of the USH2A protein plays a role in both hearing and vision.
Usher syndrome is the most common cause of deaf-
blindness (Marazita et al. 1993). Patients present with
sensorineural hearing loss and retinitis pigmentosa (RP),
with or without vestibular impairment. On the basis of
the severity and progression of the hearing loss, the age
at onset of RP, and the presence or absence of vestibular
impairment, three clinical subtypes are distinguished
that are genetically heterogeneous (Smith et al. 1994;
Ahmed et al. 2003 [and references therein]). Also, a mi-
nority of the patients are described as “atypical,” be-
cause their phenotype does not fall within one of the
three types (Otterstedde et al. 2001).
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The USH2A gene is mutated in patients with Usher
syndrome type IIa (MIM 276901), in some patients with
atypical Usher syndrome, and in a small number of pa-
tients with autosomal recessive RP (Eudy et al. 1998;
Liu et al. 1999; Adato et al. 2000; Rivolta et al. 2000;
Weston et al. 2000; Bernal et al. 2003). The gene was
described as consisting of 21 exons that span ∼250 kb
of genomic DNA at chromosome 1q41 (Eudy et al.
1998;Weston et al. 2000) (University of California Santa
Cruz [UCSC] Genome Browser, July 2003 freeze [UCSC
Genome Bioinformatics Web site]). The encoded protein
was predicted to consist of 1,546 amino acids containing
an N-terminal signal sequence and conserved functional
domains that are commonly seen in extracellular pro-
teins or in extracellular domains of proteins and that
are involved in protein-protein interactions, including
interactions with other components of the extracellular
matrix. The USH2A protein, also called usherin, was
shown to interact with type IV collagen and to be part
of basement membranes in cochlea, retina, and several
other tissues (Eudy et al. 1998; Weston et al. 2000; Bhat-
tacharya et al. 2002, 2004; Pearsall et al. 2002).
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Usher syndrome type II seems to be the most common
type of Usher syndrome (Eudy et al. 1998). In epide-
miologic studies, the ratio between Usher syndrome type
I and II varies from 2:3 to 1:2, although there is a bias
toward the western European population in the studies
(Piazza et al. 1986; Hope et al. 1997; Rosenberg et al.
1997; Spandau and Rohrschneider 2002). In certain
populations, such as the Finnish population, the Ash-
kenazi Jews, or the Acadian population in southwestern
Louisiana, speciﬁc subtypes of Usher syndrome can be
relatively frequent because of founder effects (Keats et
al. 1994; Pakarinen et al. 1995; Ness et al. 2003). On
the basis of mutation analysis, the USH2A gene is
thought to be causative in 74%–90% of cases with
Usher syndrome type II (Dreyer et al. 2000; Weston et
al. 2000; Pennings et al., in press), and thus Usher syn-
drome type IIa is the most common subtype of Usher
syndrome.
By sequence analysis of all 21 known exons and exon-
intron boundaries in patients with Usher syndrome type
II, we could detect only ∼63% of the mutant USH2A
alleles (Pennings et al., in press). Although no alternative
splicing or alternative sites for polyadenylation were re-
ported, northern blots showed transcripts of several
sizes, both shorter and longer than the known cDNAs
(Eudy et al. 1998; Huang et al. 2002). On the basis of
these results and exon predictions presented in the UCSC
Genome Browser (April 2003 freeze [UCSC Genome
Bioinformatics Web site]), we searched for as-yet-un-
characterized regions of the gene.
We developed three sets of primers in exons (29F, 30R;
30F, 33R; 63F, 64R) predicted to be 3′ of exon 21 with
the Primer3 program (Rozen and Skaletsky 2000) (table
A [online only]). RT-PCRwas performed onRNAderived
from the retinoblastoma cell line Y79 (American Type
Culture Collection), human fetal cochlea, and human
adult retina. The RNA was isolated by use of the method
described by Chirgwin et al. (1979) and treated with
DNase I (Invitrogen). Synthesis of cDNA was performed
with random hexanucleotides as primers, as described by
Luijendijk et al. (2003). After nested PCR, speciﬁc bands
were seen on agarose gel (data not shown). PCR frag-
ments were puriﬁed from gel using the QIAquick Gel
Extraction kit (Qiagen) and sequenced with the ABI
PRISM BigDye Terminator Cycle Sequencing version 2.0
kit (Applied Biosystems) and the ABI PRISM 3730 DNA
analyzer (Applied Biosystems). This revealed that at least
part of the predicted exons are transcribed. Moreover, we
could amplify a fragment with forward primers in the
known exon 20 and reverse primers in the novel exon
22, strongly suggesting that the USH2A gene is much
larger at the 3′ end than previously reported.
To further investigate which of the predicted exons are
indeed transcribed and to ﬁnd exons that are not predicted
by gene-prediction programs, forward and reverse prim-
ers were designed (table A [online only]) for a large num-
ber of predicted exons, and RT-PCR and subsequent
nested PCR were performed on RNA isolated from ret-
inoblastoma cells of the Y79 cell line. Fragments were
isolated from agarose gels and sequenced. On the basis
of the obtained results, primers were chosen to amplify
larger, overlapping cDNA fragments encompassing exons
17–29, 20–33, 30–44, 41–53, 49–63, 61–65, 63–70, and
66–72 fromhuman retinaMarathon-Ready cDNA(Clon-
tech), according to the manufacturer’s protocol. Sequence
analysis revealed that overlapping cDNA fragments were
indeed ampliﬁed, and 51 novel exons were identiﬁed. The
coding sequence of exon 21 was shown to be 14 base
pairs (bp) shorter in the long transcript(s) when compared
with the short transcript that was described elsewhere
(Eudy et al. 1998; Weston et al. 2000); the termination
codon in exon 21 is therefore excluded from the long
transcript(s). To characterize the 3′ end of the gene, a 3′
rapid ampliﬁcation of cDNA ends (RACE)was performed
using the human retina Marathon-Ready cDNA (Clon-
tech), the Advantage cDNA Polymerase kit (Clontech), a
nested gene-speciﬁc forward primer (table A [online
only]), and the Marathon-AP1 primer as the reverse
primer, according to the manufacturer’s protocol. The re-
sulting PCR product was isolated from agarose gel and
directly cloned in the pCR4-TOPO vector using the
TOPO TA Cloning kit (Invitrogen). Clones were screened
by performing internal PCR reactions from exon 70 to
exon 71 and from exon 70 to exon 72. Sequence analysis
of one of the positive clones revealed an in-frame ter-
mination codon in exon 72 and 2,888 bp of 3′ UTR. The
longest ORF extends from exon 2 to exon 72, encoding
a putative protein of 5,202 amino acids. TheUSH2A gene
now spans ∼790 kb of genomic DNA, and the 3′ UTR
ends only ∼4 kb distal to the KCTD3 gene (potassium
channel tetramerization domain containing 3) (UCSCGe-
nome Browser, July 2003 freeze [UCSC Genome Bioin-
formatics Web site]). The cDNA sequence encompassing
the longest ORF has been deposited in GenBank (acces-
sion number AY481573). The sequences of the 5′ UTR
and of exons 1–20 were derived from the previously re-
ported sequence of the known USH2A gene (GenBank
accession number NM_007123).
Besides the alternative splicing in exon 21, RT-PCR on
human retina Marathon-Ready cDNA provided evidence
for alternative splicing that leads to the skipping of exon
42, exons 50–52, and exon 62. The alternative splicing
of exon 62 is also seen in the retinoblastoma cells. Only
the skipping of exon 42 leads to interruption of the read-
ing frame. Additional studies are needed to elucidate the
functional signiﬁcance of the detected alternative splicing
and to fully characterize all of the alternative transcripts
and their spatial and temporal distribution.
The putative protein of the 5,202 amino acid residues
encoded by the longest ORF has a predicted molecular
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Figure 1 Schematic representation of the USH2A protein structure. A, The previously described short isoform. B, The putative long
isoform corresponding to the longest ORF. Novel mutations in the long isoform are depicted.
weight of 576 kD. When the predicted amino acid se-
quence is analyzed with the Pfam software (Pfam Home
Page) (Bateman et al. 2002), a protein appears that con-
sists of the previously described combination of a do-
main that is homologous to a thrombospondin N-ter-
minal-like domain (TSPN), a laminin G–like domain
(LamGL), and a pentaxin (PTX) domain, in addition to
a laminin N-terminal (LamNT) domain, 10 laminin-type
EGF-like (LE) repeats, and four ﬁbronectin type III
(FN3) repeats (Eudy et al. 1998; Weston et al. 2000)
(ﬁg. 1A), as well as two laminin G (LamG) and 28 FN3
repeats (ﬁg. 1B). Between FN3 repeats 13 and 14 there
is a partial FN3 domain and a stretch of ∼350 amino
acids with no signiﬁcant homology to any known do-
main (ﬁg. 1B). The TMHMM software predicts with
high signiﬁcance the presence of an outside-in trans-
membrane region (residues 5,041–5,063), followed by
an intracellular domain of 139 amino acids with a type
I PDZ-binding domain (DTHL) (Sheng and Sala 2001)
at its C-terminal end (ﬁg. 1B). This indicates that the
longest putative USH2A protein is a transmembrane
protein. Skipping of exon 42 is predicted to result in an
isoform of 2,742 amino acids that contains two LamGL
and eight FN3 repeats, in addition to the USH2A protein
domains that are already known to exist. Skipping of
exons 50–52 or exon 62 does not interrupt the reading
frame but can be predicted to lead to protein isoforms
without the residues 3,247–3,462 or 4,023–4,098, re-
spectively. Residues 3,247–3,462 encode most of the re-
gion between FN3 repeat 13 and 14. Deletion of amino
acids 4,023–4,098 removes the C-terminal part of an
FN3 repeat and the N-terminal part of the following
one, leading to an isoform that is one FN3 repeat shorter.
Expression was studied for both the short and the long
isoforms in fetal and adult tissues. A semiquantitative
RT-PCR was performed, as described by Luijendijk et
al. (2003), and 10 ml aliquots were taken after 25, 30,
and 35 PCR cycles. For the short isoform, primers were
designed in exon 20 and in the 3′ UTR of exon 21 (table
A [online only]). In fetal tissues, bands were visible on
agarose gel only after 35 PCR cycles and were strongest
in eye, cochlea, and heart (ﬁg. 2A). Weak bands were
seen in brain, CNS, intestine, skeleton, tongue, kidney,
and lung. No expression was detectable in stomach and
liver. In adult tissues, the highest expression was seen in
neural retina, already visible after 25 cycles (ﬁg. 2A). In
testis and retinal pigment epithelium (RPE)–choroid, ex-
pression was seen after 30 cycles. In brain, heart, kidney,
and liver, expression was seen only after 35 cycles. The
expression in RPE-choroid might be due to contami-
nation with cells of the neural retina since RPE-choroid
is extremely difﬁcult to isolate without any remains of
neural retina. Expression of the long isoform(s) was
tested using primers in exons 40 and 41 (ﬁg. 2B) and
primers in exons 59 and 60 (data not shown). The two
primer combinations revealed the same expression pat-
tern. No expression was detected in fetal tissues after
35 PCR cycles (ﬁg. 2B). Expression of the long isoform
was, as was seen for the short transcript, highest in adult
neural retina and was visible after 25 PCR cycles. After
30 cycles, expression was detectable in heart and kidney.
We can conclude that, in fetal tissues and in adult tissues
other than retina, USH2A transcripts are not abundant;
this is especially true for the transcripts encoding the
long isoform(s). For testis, RT-PCR suggests differential
expression, since a clear fragment was only seen for the
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Figure 2 Expression proﬁle analysis by semiquantitative RT-PCR analysis of USH2A. A, RT-PCR speciﬁc for the transcript encoding the
short isoform. B, RT-PCR speciﬁc for transcript(s) encoding the long isoform(s). Samples were taken after 25, 30, and 35 cycles. The RNA
used for RT-PCR analyses was derived from the following tissues: fetal (1) eye, (2) cochlea, (3) brain, (4) CNS, (5) stomach, (6) intestine, (7)
skeleton, (8) heart, (9) tongue, (10) kidney, (11) lung, and (12) liver; adult (1) retina, (2) RPE-choroid, (3) cornea, (4) brain, (5) skeletal muscle,
(6) heart, (7) kidney, (8) lung, (9) liver, and (10) testis. Expression of the short isoform was detected in several fetal and adult tissues, whereas
expression of the long isoform was only detected in adult retina (predominantly), heart, and kidney.
short transcript. Although not detected in expression
proﬁling, there is very low expression of the long iso-
form(s) in fetal cochlea, since several fragments could
be ampliﬁed by nested PCR. Comparison of our data
with previous data on USH2A expression is difﬁcult,
since previous studies do not discriminate between the
long and the short isoforms. However, the highest ex-
pression of USH2A in retina is in agreement with the
results of Huang et al. (2002), who analyzed USH2A
transcripts in adult mouse and rat tissues, and with the
results of Eudy et al. (1998), who studied some fetal
human tissues, including eye.
To address the question of whether the putative long
USH2A protein is essential for normal functioning of the
cochlea and the retina, we sequenced the protein-coding
parts and ﬂanking intron sequences of exons 22–72, as
described above, in 2 unrelated familial subjects and 10
isolated Dutch patients with USH2. In these patients, only
one pathogenic mutation was detected after sequencing
exons 1–21 (Pennings et al., in press). Primer sequences
are given in table B (online only). The study was approved
by the local ethics committee, and informed consent was
obtained from all patients and healthy family members.
In four patients, a truncating mutation was detected in
the novel 3′ region of the gene (ﬁg. 3). The c.11864GrA
substitution in exon 61 introduces a termination codon
(Trp3955Ter) in patients 20608 and 20662. Patient
20608 was already known to carry the c.949CrA
(Arg317Arg) mutation, which was predicted to create
an additional 5′ splice site in exon 5. Patient 20662 car-
ries the Cys419Phe (c.1256GrT) mutation, in addition
to the Trp3955Ter mutation. A nonsense mutation,
c.14525CrA (Ser4842Ter) in exon 66, was found in pa-
tient 20625, who was heterozygous for the 2299delG
(Glu767fs) mutation. In patient 20599, who was also
previously found to be heterozygous for the 2299delG
(Glu767fs) mutation, a deletion of a TG dinucleotide in
exon 44 was predicted to cause a frameshift (Val2908fs).
Two missense mutations in exon 63, Arg4115Cys and
Thr4425Met, were found on the same allele in patient
20609, who also carries the Cys419Phe mutation (ﬁg. 3).
None of the ﬁve mutations was found in 94 ethnically
matched control samples.
DNA samples of additional family members were
available for two of the patients, to prove that the iden-
tiﬁed nucleotide changes were not located on the same
allele as the previously detected mutations. For patient
20608, we could show by sequence analysis that the
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Figure 3 Mutations in the novel exons of the USH2A gene. In each panel, the upper sequence pane shows the heterozygous mutation in
the patient. The lower pane depicts the wild-type sequence.
c.949CrA mutation is derived from the mother and the
c.11864GrA mutation came from the father (data not
shown). In a healthy son of patient 20662, we detected
the c.1256GrT mutation but not the c.11864GrA mu-
tation, indicating that these mutations are not part of a
complex USH2A allele. To prove the pathogenicity of
either of the two amino acid substitutions, or the com-
bination of the two, segregation analysis in family mem-
bers and functional studies are needed. The presence of
pathogenic mutations in the novel exons of the USH2A
gene indicates the functional signiﬁcance of at least one
of the long isoforms of the USH2A protein for normal
functioning of the cochlea and retina. This is further
corroborated by a retina-derived mouse cDNA clone
(GenBank accession number AK044734) that encodes a
peptide with 69% identity to the putative long human
USH2A isoform(s). Also, exons that encode FN3 repeats
are predicted in the syntenic region of both mouse and
rat (Mouse Genome Browser, February 2003 freeze; Rat
Genome Browser, June 2003 freeze [UCSC Genome
Bioinformatics Web site]).
Sequencing exons and exon-intron boundaries of
other large genes involved in autosomal recessive dis-
eases that display a high allelic heterogeneity, such as
the ABCA4 gene, detected ∼80% of the mutations
(Shroyer et al. 2001). By sequencing exons 1–21, we
identiﬁed ∼63%of the mutatedUSH2A alleles (Pennings
et al., in press). From this we can deduce that not more
than ∼20% of the mutations in patients with Usher syn-
drome type IIa are expected to be in the novel exons.
We showed that mutations in the long isoform(s) of
USH2A can be causative for Usher syndrome in com-
bination with a mutation in exons 1–21. The question
remains whether two alleles with a mutation in the novel
exons can also lead to Usher syndrome. Symptoms due
to defects in other organs might occur, since USH2A
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transcripts encoding the long isoform(s) are present in
heart and kidney. Also, the USH2A protein was shown—
by use of antibodies that are likely to detect both the
short and the long isoforms—to be present in several
organs in addition to retina and cochlea. (Bhattacharya
et al. 2002; Pearsall et al. 2002). Alternatively, this ge-
notype might lead to nonsyndromic hearing loss or RP.
It is also interesting to note that the Cys759Phe amino
acid substitution was found to be homozygously present
in patients with RP and also in nonsymptomatic indi-
viduals (Rivolta et al. 2000; Bernal et al. 2003). This
might suggest that this mutation is a polymorphism that
is linked to a so-far-unknown mutation in one of the
novel 3′ exons of the gene in the patients with RP and
that two mutations in the long isoform(s) cause non-
syndromic RP. This is in agreement with the very low
transcript levels of the long isoform(s) in cochlea.
The combination of domains predicted for the USH2A
isoforms is not present in any other protein (PfamHome
Page), which might suggest unique functions. The pre-
viously known short isoform is an extracellular protein.
It has been suggested that LE domains, also present in
this short isoform, may interact with collagen IV to sta-
bilize the USH2A protein in the basement membrane
(Bhattacharya et al. 2004). The identiﬁcation of the 3′
exons encoding the putative long USH2A isoform(s)—
of which at least some have an intracellular domain—
reveals new opportunities to study the function of the
USH2A gene. It is interesting that the CDH23 gene is
involved in Usher syndrome type I and encodes a protein
that is, as are the long putative isoforms of USH2A,
composed of a large extracellular region and a trans-
membrane region followed by an intracellular domain
with a PDZ-binding domain at its C-terminal end (Bolz
et al. 2001; Bork et al. 2001; Siemens et al. 2002).
CDH23 interacts with harmonin through its PDZ-bind-
ing domain and is suggested to be part of a protein
complex necessary for the development of the hair cell
stereocilia in the inner ear (Boe¨da et al. 2002).Mutations
in genes encoding other components of this complex,
such as harmonin, myosin VIIa, and sans, also can be
causative for Usher syndrome type I (Ahmed et al. 2003
[and references therein]). This illustrates that, besides
providing new handles for studying USH2A function,
the long isoform(s) of USH2A might guide us to a pro-
tein complex with other components that are defective
in patients with Usher syndrome type II. So far, two other
loci are known for Usher syndrome type II, for which
the causative genes have not yet been identiﬁed (Hmani
et al. 1999; Pieke-Dahl et al. 2000).
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